Document And Entity Information Document Information [Table] Document Information [Line Items] Document Quarterly Report Document Transition Report Document Type Document Period End Date Entity Registrant Name Entity Tax Identification Number Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity File Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province City Area Code Local Phone Number Entity Small Business Entity Emerging Growth Company Entity Shell Company Title of 12(b) Security Security Exchange Name Trading Symbol Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Available-for-sale Securities, Debt Securities Marketable securities Fair Value Accounts and Other Receivables, Net, Current Accounts receivable - related party Prepaid Expense and Other Assets, Current Prepaid and other current assets Total of prepaid and other current assets Assets, Current Total current assets Current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Equity Method Investments Investment in Angel Pharmaceuticals Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Operating Lease, Liability, Current Operating lease liability Carrying value as of the balance sheet date of accrued liabilities and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Liabilities and Other Liabilities, Current Accrued and other liabilities Total of accrued and other liabilities Liabilities, Current Current liabilities Total current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023 Common Stock, Value, Issued Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2024 and December 31, 2023; 49,038,582 shares issued and outstanding at March 31, 2024 and December 31, 2023 Additional Paid in Capital, Common Stock Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred stock, shares authorized for issuance Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common stock, shares authorized for issuance Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Amount of interest income and other expense netted together. Interest income and other expense, net Amount of sublease income in connection with related party transactions. Sublease Income, Related Party Sublease income - related party Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss before equity method investment Net income (loss) before income tax Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Equity method investments realized gain loss Income (loss) from equity method investment Income (loss) from equity method investment Net loss Net loss Net loss - basic and diluted Earnings Per Share, Basic Net loss per share, basic Earnings Per Share, Diluted Net loss per share, diluted Weighted Average Number of Shares Outstanding, Basic Shares used to compute net loss per share, basic Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Shares used to compute net loss per share, diluted Weighted average diluted shares outstanding Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Unrealized gain (loss) on marketable securities Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Cumulative foreign currency translation adjustment Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-In Capital [Member] Additional Paid-In Capital Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income (Loss) Retained Earnings [Member] Accumulated Deficit Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, Stock Options Exercised Common stock issued on exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Outstanding Options, Exercised Common stock issued on exercise of stock options (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax Unrealized gain (loss) on marketable securities CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Accretion (Amortization) of Discounts and Premiums, Investments Accretion related to marketable securities Share-based Compensation Stock-based compensation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable - related party Increase (Decrease) in Prepaid Expense and Other Assets Prepaid and other current assets Amount of increase (decrease) in operating lease right of use asset. Increase (Decrease) In Operating Lease Right Of Use Asset Operating lease right-of-use asset Increase in operating lease right-of-use asset Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities Amount of increase (decrease) in operating lease liabilities. Increase Decrease In Operating Lease Liabilities Operating lease liability Increase in the operating lease liability Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in operating activities Cash flows from investing activities Payments to Acquire Available-for-sale Securities Purchases of marketable securities Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Maturities of marketable securities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by investing activities Cash flows from financing activities Proceeds from Stock Options Exercised Proceeds from exercise of common stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of the period Cash and cash equivalents at beginning of the period Organization Nature of Operations [Text Block] Organization Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Equity Method Investment Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity Method Investment n/a License and Collaboration Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] License and Collaboration Agreements Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Common Stock Stockholders' Equity Note Disclosure [Text Block] Common Stock Stock Option Plans The entire disclosure for share-based compensation plan details. Disclosure of Share-Based Compensation Plans [Text Block] Stock Option Plans Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Income Taxes Income Tax Disclosure [Text Block] Income Taxes Facility Lease Lessee, Operating Leases [Text Block] Facility lease Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Disclosure of accounting policy of unaudited interim financial information. Unaudited Interim Financial Information [Policy Text Block] Unaudited Interim Financial Information Use of Estimates, Policy [Policy Text Block] Use of Estimates Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk and Other Risks and Uncertainties Segment Reporting, Policy [Policy Text Block] Segments Significant Accounting Policies [Text Block] Significant Accounting Policies Equity Method Investments [Policy Text Block] Investments in Equity Securities New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of net loss per share, basic and diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of antidilutive securities excluded from calculation of diluted net loss per share Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value of assets measured at fair value on a recurring basis, by level of fair value hierarchy Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of fair value of available for sale marketable securities Equity Method Investments [Table Text Block] Schedule of financial information of Angel Pharmaceuticals Co. Condensed Balance Sheet [Table Text Block] Schedule of balance sheet components Tabular disclosure of shares of common stock reserved for issuance. Schedule of Common Stock, Shares Reserved for Issuance [Table Text Block] Schedule of shares of common stock reserved for issuance Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option activity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of expenses relating to employee and non-employee stock-based awards Lessee, Lease, Description [Table] Lease Contractual Term [Axis] Lease Contractual Term [Domain] Identified as quarter ended March 31, 2024. Quarter Ended March 31 2024 [Member] As of March 31, 2024 Identified as fiscal year ended December 31, 2023. Year Ended 2023 [Member] As of December 31, 2023 Lessee, Lease, Description [Line Items] Schedule of Operating Lease Costs Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Minimum rental commitments Sale of Stock [Axis] Sale of Stock [Domain] Secondary offering of stock to the public. Follow-on Public Offering Over-Allotment Option IPO Sale of Company's equity shares through a registered direct offering. Registered Direct Offering [Member] Registered Direct Offering Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Exchange Warrants Warrants Common Stock Number Of Shares Par Value And Other Disclosures [Abstract] Shares of common stock reserved for issuance, on an as-converted basis Public Offerings Shares Issued, Price Per Share Share offering price Combined offering price per share of pre-funded and common warrants Proceeds from Issuance Initial Public Offering Net proceeds from IPO Proceeds from issuance of common stock Proceeds from sale of stock Cash, Cash Equivalents, and Short-term Investments Cash, cash equivalents and marketable securities Cash, cash equivalents and short-term marketable securities Stock Issued During Period, Shares, New Issues Common shares issued in transaction Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase common shares Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Risks and Uncertainties [Abstract] Concentrations of Credit Risk and Other Risks and Uncertainties The number of financial institutions within which the entity deposits substantially all of its cash and cash equivalents. Number Of Financial Institutions Number of financial institutions used for cash and cash equivalent deposits Segments Number of Operating Segments Number of operating segments Earnings Per Share, Basic and Diluted [Abstract] Net Loss Per Share, Basic and Diluted Net Income (Loss) Attributable to Parent [Abstract] Numerator: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Denominator: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] An arrangement whereby the employee or non-employee holder of the instrument is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Outstanding options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti dilutive securities were excluded from the calculation of diluted net loss per share Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 1 Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Assets, Fair Value Disclosure [Abstract] Assets Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Investments, Fair Value Disclosure Marketable securities Assets, Fair Value Disclosure Total Assets Maximum amount of time remaining before marketable securities mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Maximum Remaining Maturity Of Marketable Securities Maximum remaining maturity of marketable securities Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instruments [Domain] Debt Securities [Member] U.S. Treasury securities U.S. Government agency securities Schedule of Available-for-sale Securities [Line Items] Available for sale marketable securities Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract] Fair value of available for sale marketable securities Available-for-sale Securities, Amortized Cost Basis Amortized Cost Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Schedule of Equity Method Investments [Table] Investment, Name [Axis] Investment, Name [Domain] Represents information pertaining to Angel Pharmaceuticals Co., Ltd. Angel Pharmaceuticals Schedule of Equity Method Investments [Line Items] Equity Method Investment, Ownership Percentage Ownership interest (as percent) Percentage of equity reserved for issuance under employee stock purchase. Percentage of Equity Reserved For Issuance Under Employee Stock Purchase Equity reserved (as percent) Income (Loss) from Equity Method Investments Share of loss from investments accounted for using the equity method Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Domain] Assets, Noncurrent Non-current assets Liabilities, Noncurrent Non-current liabilities Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Agreement granting the entity license to certain technology and intellectual property of the counterparty. Licensing Agreement Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to the Scripps Research Institute. Scripps Research Institute Represents the information pertaining to Vernalis (R&D) Limited. Vernalis (R&D) Limited Information pertaining to Monash License. Monash License Income Statement Location [Axis] Income Statement Location [Domain] Research and development Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum Amount of a one-time cash payment made to the counterparty upon entering into a license or collaboration agreement. License and Collaboration Agreements, Upfront Cash Payment Made One-time cash payment The minimum annual fee the entity is obligated to pay to the counterparty under the license or collaboration agreement. License and Collaboration Agreements, Minimum Annual Fee Minimum annual fee The aggregate potential amount of payments the entity may be required to make to the counterparty based on achievement of milestones under the license or collaboration agreement. License and Collaboration Agreements, Aggregate Potential Milestone Payments Aggregate potential milestone payments The amount of payments to the entity that are required to be made to the counterparty based on achievement of milestones under the license or collaboration agreement. License And Collaboration Agreements Milestone Payments Made Milestone payments made Period of written notice the entity is required to provide for termination of the license or collaboration agreement. License and Collaboration Agreements, Period of Written Notice for Termination Period of written notice to terminate Prepaid Expense and Other Assets, Current [Abstract] Prepaid and Other Current Assets Interest Receivable Interest receivable Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research And Development Manufacturing Expenses Prepaid research and development manufacturing expenses Amount of asset related to consideration paid in advance for facility expenses. Prepaid Facility Expenses Prepaid facility expenses Prepaid insurance Prepaid insurance Other Assets, Current Other Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Laboratory equipment Computer equipment and purchased software. Computer equipment and purchased software Leasehold improvements Property, Plant and Equipment [Line Items] Property and Equipment Property, Plant and Equipment, Gross Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization No definition available. Accrued Liabilities And Other Liabilities Current [Abstract] Accrued and Other Liabilities Represents the carrying value, as of the balance sheet date, of obligations incurred and payable related to clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer). Accrual For Preclinical And Clinical Trial, Current Accrued clinical trial expense Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing expense (due within one year or within the normal operating cycle if longer). Accrued Manufacturing Expense, Current Accrued manufacturing expense Employee-related Liabilities, Current Personnel related Accrued Professional Fees, Current Accrued legal and accounting Other Accrued Liabilities, Current Other Depreciation, Depletion and Amortization, Nonproduction Depreciation expense Schedule of Stock by Class [Table] Sale of stock through an at-the-market equity offering program under a sales agreement. At-the-market offering Jefferies LLC [Member] Jefferies LLC Represents the information pertaining to 2023 sales agreement. 2023 Sales Agreement Class of Stock [Line Items] Common Stock Represents the number of votes per share of common stock. Common Stock, Voting Rights, Number of Votes Per Share Number of votes per share of common stock Dividends, Common Stock Dividends on common stock The amount of aggregate gross proceeds from the sale of stock through an at-the-market equity offering under the sales agreement. Potential Gross Proceeds From Sale Of Stock Under Agreement Potential gross proceeds Amount of stock issuance costs, as a percentage of gross proceeds, due to sales agent upon sale of stock per agreement. Stock Issuance Costs Percentage Stock issuance costs, as a percent of gross proceeds Amount of common stock remained available for sale under the Sales Agreement. Common Stock Remained Available For Sale Common shares available for future sale Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares Available for Grant, Ending Balance Shares Available for Grant, Opening Balance Shares available for future option grants Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding Options, Ending Balance Outstanding Options, Opening Balance Outstanding options Represents the number of shares that are reserved for the employee stock purchase plan. Number of Shares Reserved for Employee Stock Purchase Plan Shares reserved for employee stock purchase plan Common Stock, Capital Shares Reserved for Future Issuance Total Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] The entity's 2014 plan under which it may grant stock-based awards. 2014 Plan The entity's 2016 Equity Incentive Award Plan under which it may grant stock-based awards. 2016 Plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Option Plans Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Maximum exercise term Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Exercise price of common stock of its fair value (as a percent) Represents the maximum number of options that if forfeited or lapse, may be reissued under another equity incentive award plan. Maximum Number of Options Forfeited or Lapsed That May Be Reissued Maximum number of options that may be re-issued under the 2016 plan No definition available. Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward] Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Shares Available for Grant, Additional Shares Authorized Gross number of share options (or share units) granted during the period. Share-Based Compensation, Shares Available for Grant, Options, Grants in Period Shares Available for Grant, Options Granted The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Share-Based Compensation, Shares Available for Grant, Forfeitures in Period Shares Available for Grant, Options Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Outstanding Options, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Outstanding Options, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Options - Weighted Average Exercise Price, Ending Balance Outstanding Options - Weighted Average Exercise Price, Opening Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Outstanding Options - Weighted Average Exercise Price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding Options - Weighted Average Exercise Price, Forfeited Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] General and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation Allocated Share-based Compensation Expense Stock-based compensation expense Income Tax Examination [Table] Income Tax Examination [Line Items] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract] Income Tax Expense (Benefit) Income tax benefits Burlingame, California Office Related Party [Axis] Related Party [Domain] Lessee Disclosure [Abstract] Lease Area of Real Estate Property Area of leased facility Lessee Leasing Arrangements, Operating Leases, Term of Contract Lease term Represents the amount of lease incentives and free rent that were provided by the landlord. Landlord Provided Free Rent And Lease Incentives Area of property subleased. Area Of Property Subleased Area of property subleased Lease, Cost [Abstract] Operating lease cost Operating Lease, Cost Operating lease costs Variable Lease, Cost Costs of non-lease components (previously common area maintenance) Lease, Cost Total operating lease cost Lessee, Operating Lease, Description [Abstract] Other Information Operating Lease, Payments Operating cash flows used for operating lease Operating Lease, Weighted Average Remaining Lease Term Remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Discount rate Operating Lease Liabilities, Payments Due [Abstract] Minimum rental commitments 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024* Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2024 Lessee, Operating Lease, Liability, Payments, Due Total lease payments Amount of lessee's imputed interest expense on future lease liability payments. Lessee Operating Lease Liability Imputed interest Less: imputed interest Operating Lease, Liability Total Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Domain] Secured debt Line of Credit Facility [Line Items] Line of credit Line of Credit Facility, Maximum Borrowing Capacity Line of credit Security Deposit Security deposit Schedule of Related Party Transactions, by Related Party [Table] Represents information pertaining to ICON Plc. ICON plc Related Party Transaction [Line Items] Related Party Transactions Due from Related Parties, Current Accounts receivable n/a Related Party Stock Transactions [Abstract] Owners of More Than 5% of Our Common Stock or Board of Directors The amount of research service costs billed to related parties during the period. Related party research service costs The amount of third party costs billed to related party during the period. Related Party, Third Party Costs Third-party costs The amount of clinical trial expense incurred during the period. Clinical Trial Expense Clinical trial expense Subsequent Event [Table] Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Common Stock Warrants [Member] Common Warrants Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Pre-Funded Warrants [Member] Pre-Funded Warrants Represents information pertaining to institutional investors and significant shareholders affiliated with the Company's directors, CEO and other executive officers. Institutional Investors and Significant Shareholders [Member] Institutional Investors and Significant Shareholders Subsequent Event [Line Items] Subsequent Event Exercise price per share of pre-funded warrants in lieu of common share warrants. Exercise price of pre-funded warrants Exercise price of pre-funded warrants in lieu of common share warrants